AARD (Aardvark Therapeutics) Total Liabilities: $11.60 Mil (As of Mar. 2026)


AARD Aardvark Therapeutics Inc AARD
12 GF Score
Price $5.18
! 1 Warning Sign
View Full Analysis

What is Aardvark Therapeutics Total Liabilities?

Aardvark Therapeutics AARD +8.14% 12 Total Liabilities is $11.60 Mil as of Mar. 2026. GuruFocus rates AARD with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Aardvark Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 was $11.60 Mil.

Aardvark Therapeutics's quarterly Total Liabilities declined from Sep. 2025 ($10.85 Mil) to Dec. 2025 ($10.55 Mil) but then increased from Dec. 2025 ($10.55 Mil) to Mar. 2026 ($11.60 Mil).

Aardvark Therapeutics's annual Total Liabilities increased from Dec. 2023 ($45.34 Mil) to Dec. 2024 ($132.15 Mil) but then declined from Dec. 2024 ($132.15 Mil) to Dec. 2025 ($10.55 Mil).

Aardvark Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Aardvark Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aardvark Therapeutics Total Liabilities Chart

Aardvark Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Liabilities
44.68 45.34 132.15 10.55

Aardvark Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.34 10.55 10.85 10.55 11.60
AARD
12GF Score
Aardvark Therapeutics Inc AARD
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aardvark Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Aardvark Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=10.548+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=10.55

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=117.181-106.633
=10.55

Aardvark Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=11.604+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=11.60

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=98.59-86.986
=11.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $11.60 Mil mean?
Aardvark Therapeutics (AARD) has a Total Liabilities of $11.60 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Aardvark Therapeutics and its competitors.
Is Aardvark Therapeutics' Total Liabilities too high?
Aardvark Therapeutics' current Total Liabilities is $11.60 Mil. Overall, Aardvark Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Aardvark Therapeutics' Total Liabilities compare to KLRS and VANI?
Aardvark Therapeutics' Total Liabilities of $11.60 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Aardvark Therapeutics and its competitors. Aardvark Therapeutics's current Total Liabilities is $11.60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aardvark Therapeutics stock overvalued right now?
Aardvark Therapeutics (AARD) has a current Total Liabilities of $11.60 Mil. The current Total Liabilities is $11.60 Mil. Aardvark Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Aardvark Therapeutics (AARD), the current Total Liabilities is $11.60 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aardvark Therapeutics Business Description

Address 4370 La Jolla Village Drive, Suite 1050, San Diego, CA, USA, 92122
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
12GF Score

Get the complete analysis for AARD

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.18
Price